While ARL5B was prioritized due to its consistent downregulation in Y79 and Weri-Rb1 cells and its functional association with retinoblastoma cell migration—supported by preliminary overexpression experiments—the remaining candidate proteins require systematic validation and will be the focus of future studies. The gene discussed is ARL5B; the disease is retinoblastoma.